Skip to main content

BAXTER LAUNCHES OLIMEL N12

Press Release
  • BAXTER LAUNCHES OLIMEL N12 IN EUROPE TO MEET HIGH PROTEIN NEEDS IN CRITICALLY ILL PATIENTS

     

PDF

KRACOW, Poland - August 29, 2019

  • The new parenteral nutrition (PN) formulation is available in Europe

following its launch in Canada

  • Olimel N12 is a ready-to-use formulation designed to meet the needs of high stress patients
  • Olimel N12 combines a high protein formulation with low glucose content, resulting in the lowest energy to protein ratio currently available in a standardized, triple-chamber bag.
  • Both European Society of Clinical Nutrition and Metabolism (ESPEN) and American Society for Parenteral and Enteral Nutrition (ASPEN) guidelines recommend a higher protein intake for critically ill and oncological patients.

 

KRACOW, Poland, August 29, 2019 - Baxter International Inc. (NYSE: BAX), a global leader in clinical nutrition, announced today the European launch of Olimel N12, the new addition to the company’s olive oil-based parenteral nutrition (PN) triple-chamber bag portfolio. The European launch will be at the 41st Congress of the European Society of Clinical Nutrition and Metabolism (ESPEN), taking place from August 31 to September 3,2019.

Olimel N12 combines a high protein formulation with low glucose content, resulting in the lowest energy to protein ratio currently available in a standardized, triple-chamber bag. The new formulation contains:

  • 76g of amino acid per liter, designed to meet protein targets in lower fluid volumes.
  • Only 73g of glucose per liter, helping to reduce the potential glycemic load and subsequent risk of hyperglycemia.
  • An olive oil-based lipid emulsion, which may preserve immune function[i]-[ii]-[iii]-[iv]-[v]

“Around 40% of patients admitted to hospital are either malnourished or at risk of worsening nutrition status due to their medical condition. In some groups such as gastric, pancreatic and esophageal cancer patients, this can be as high as 60%. Malnutrition can have a significant impact on both clinical and healthcare system-related outcomes. It is typically associated with higher infection rates, reduced quality of life, increased morbidity and mortality, as well as increased length of stay and healthcare costs” – said Pilar Gargia-Lorda, medical director, Clinical Nutrition, Baxter Europe.

“Patients’ nutritional needs can change throughout their illness and recovery, and the balance of nutrients in any nutritional therapy is important. Achieving adequate nutritional intake through oral or enteral routes is not always possible and, in such cases, intravenous feeding is required to maintain and improve the nutritional state” – she added.

The fact that 50% of critically ill patients do not receive adequate nutritional intake poses a challenge. Both ESPEN and the American Society for Parenteral and Enteral Nutrition (ASPEN) recommend a higher protein intake for this patient group, with reduced calorie. These patients are also often restricted in the amount of fluid they can receive. Critical illness is associated with rapid protein breakdown and muscle loss.[vi] Studies have shown that optimal nutrition, involving both moderate energy intake and high protein supply, is associated with reduced mortality.[vii] A higher protein intake has also been linked to improved kidney function.[viii]

Until now, ready-to-use parenteral nutrition options did not provide the necessary balance of macronutrients, with clinicians unable to meet protein goals without increasing the risk of excessive calorie and glycemic provision potentially leading to sub-optimal clinical outcomes.

The new Olimel N12 formulation is readily available in Germany, the United Kingdom, Austria, the Netherlands, Sweden, Norway and Denmark. The product is expected to arrive in France, Italy, Spain, Ireland, Portugal and Finland by the end of the year. 

 

Clinical Nutrition Business

Baxter has been assisting clinicians in treating patients' diverse nutrient needs since the 1940s, when the company first introduced liquid proteins in the form of amino acids. Since then, Baxter has continued to advance nutritional therapy. Baxter pioneered the world's first "triple-chamber system" internationally for IV nutrition, which provides many of the essential ingredients of balanced nutrition – protein, carbohydrates, lipids and electrolytes in a single container – simplifying the preparation of parenteral nutrition for patients.

Today, Baxter provides one of the broadest parenteral nutrition portfolios globally, which includes premix IV solutions, vitamins and lipids, as well as pharmacy workflow management, labeling and compounding technology.  Baxter's lipid emulsions are available globally in multi-chamber, ready-to-use emulsions, and single-emulsion bags that can be added to a compounded or premixed bag to ensure clinicians can prescribe appropriate well-balanced therapy for their individual patients.

About Baxter

Every day, millions of patients and caregivers rely on Baxter’s leading portfolio of critical care, nutrition, renal, hospital and surgical products. For more than 85 years, we've been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen. With products, technologies and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations.

 

 

 

* Important Safety/Risk Information for OLIMEL N12

Therapeutic indications:

PERIOLIMEL/OLIMEL are indicated for parenteral nutrition for adults and children greater than 2 years of age when oral or enteral nutrition is impossible, insufficient or contraindicated.

PERIOLIMEL/OLIMEL are not recommended for use in children less than 2 years of age due to inadequate composition and volume.

Contraindications:

The use of PERIOLIMEL/OLIMEL with and without electrolytes are contra-indicated in the following situations:

  • In premature neonates, infants and children less than 2 years of age
  • Hypersensitivity to egg, soybean, or peanut proteins, or to any of the active substances or       excipients
  • Congenital abnormalities of amino acid metabolism
  • Severe hyperlipidaemia or severe disorders of lipid metabolism characterized by hypertriglyceridemia
  • Severe hyperglycemia

The use of PERIOLIMEL/OLIMEL with electrolytes are contra-indicated in the following situations:

  • Pathologically-elevated plasma concentrations of sodium, potassium, magnesium, calcium, and/or phosphorus.

Baxter and Olimel are registered trademarks of Baxter International Inc


[Reference Sources]

i Jia Nutrition Journal 2015;14-119.

ii Calder PC, et al. Intensive Care Med 2010;36:735-49.

iii Granato D, et al. JPEN J Parenter Enteral Nutr 2000;24:113-8.

iv Olthof E, et al. Clin Nutr 2013;32:643-649. 4. Pontes-Arruda A, Clin Nutr Suppl 2009;4:19-23. 5.

v Waitzberg DL, et al. JPEN J Parenter Enteral Nutr 2006;30:351-67.

vi Jia Nutrition Journal 2015;14-119

vii Zusman 2016

viii Calder P